Comparing the current results to its competitors, Achieve Life Sciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 13.58 %, recorded in the same quarter.
Achieve Life Sciences Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 331.52 %
Achieve Life Sciences Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, universities, and other research institutions worldwide, with a focus on smoking cessation. In the United States, two non-nicotine prescription treatments for smoking cessation are currently available: varenicline, marketed by Pfizer as Chantix, and bupropion, formerly marketed by GlaxoSmithKline as Zyban. Both treatments are now available in generic formulations. Competitors such as GlaxoSmithKline and Pfizer have historically invested significant resources in developing and commercializing smoking cessation products and are expected to continue doing so.
April 21, 2025
In recent weeks, Achieve Life Sciences Inc. has garnered attention following the publication of its Phase 3 ORCA-3 trial results on cytisinicline, a potential new tool for smoking cessation. The findings, published in JAMA Internal Medicine, highlight the drug s ability to significantly increase quit rates and reduce nicotine cravings among participants when compared to a placebo. The study adds to the growing evidence suggesting that cytisinicline may serve as a valuable option for individuals looking to overcome nicotine dependence. Key Findings from the ORCA-3 TrialThe ORCA-3 trial evaluated the efficacy of cytisinicline in smoking cessation in a substantial cohort. Results demonstrated that participants ...
February 29, 2024
In a significant development, Achieve Life Sciences recently announced that it has successfully reached an agreement with the U.S. Food and Drug Administration (FDA) regarding the requirements for long-term exposure data on Cytisinicline, a promising compound for smoking cessation. The agreement marks a major step forward for Achieve Life Sciences as it moves closer to obtaining FDA approval for Cytisinicline.According to the terms of the agreement, Achieve Life Sciences will conduct an open-label exposure trial, which is set to commence in the second quarter of 2024. This trial is a pivotal step toward gathering substantial data on the long-term effects and safety profile of Cytisinicline. The company belie...
Sources:
Achieve Life Sciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Achieve Life Sciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
